Inj ustekinumab-aauz 1 mg
Products billed under this code include Otulfi, Ustekinumab-AAUZ.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Otulfi, Ustekinumab-AAUZ.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Otulfi | FreseniUS Kabi USA, LLC | 65219-0822-05 | 45 | $596.07 |
| Otulfi | FreseniUS Kabi USA, LLC | 65219-0824-01 | 45 | $596.07 |
| Otulfi | FreseniUS Kabi USA, LLC | 65219-0826-26 | 90 | $1,192.14 |
| Otulfi | FreseniUS Kabi USA, LLC | 65219-0828-05 | 130 | $1,721.98 |
| Ustekinumab-AAUZ | FreseniUS Kabi USA, LLC | 65219-0862-01 | 45 | $596.07 |
| Ustekinumab-AAUZ | FreseniUS Kabi USA, LLC | 65219-0866-26 | 90 | $1,192.14 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $13.246 | +$0.092 | 1 MG | Inj ustekinumab-aauz 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $13.154 | −$0.139 | 1 MG | Inj ustekinumab-aauz 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $13.293 | −$19.664 | 1 MG | Inj ustekinumab-aauz 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $32.957 | −$0.131 | 1 MG | Inj ustekinumab-aauz 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $33.088 | – | 1 MG | Inj ustekinumab-aauz 1 mg | v1, posted September 8, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.